Anzeige
Meldung des Tages: Unter dem Radar, voll finanziert: Beginnt jetzt der nächste Gold-Run?

Trevi Therapeutics News

Aktie
WKN:  A2PHHF ISIN:  US89532M1018 US-Symbol:  TRVI Branche:  Biotechnologie Land:  USA
14,04 $
+0,70 $
+5,25%
11,905 € 14.04.26
Depot/Watchlist
Marktkapitalisierung *
975,56 Mio. €
Streubesitz
-
KGV
-9,16
Index-Zuordnung
-

Trevi Therapeutics News

22.01.26 - PR Newswire
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA) PR ...
08.01.26 - PR Newswire
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference PR Newswire
04.12.25 - PR Newswire
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer PR Newswire
13.11.25 - PR Newswire
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates PR Newswire
06.11.25 - PR Newswire
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025 PR Newswire
04.11.25 - PR Newswire
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference PR Newswire
08.10.25 - PR Newswire
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting PR Newswire
18.09.25 - PR Newswire
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025 PR Newswire
28.08.25 - PR Newswire
Trevi Therapeutics to Participate in Upcoming September Conferences
Trevi Therapeutics to Participate in Upcoming September Conferences PR Newswire
07.08.25 - PR Newswire
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates PR Newswire
31.07.25 - PR Newswire
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025 PR Newswire
29.07.25 - PR Newswire
Trevi Therapeutics to Participate in Upcoming August Conferences
Trevi Therapeutics to Participate in Upcoming August Conferences PR Newswire
05.06.25 - PR Newswire
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares PR Newswire
03.06.25 - PR Newswire
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock PR Newswire
02.06.25 - PR Newswire
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
Trevi Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
02.06.25 - PR Newswire
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough PR Newswire
01.06.25 - PR Newswire
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary ...
29.05.25 - PR Newswire
Trevi Therapeutics to Participate in Upcoming June Conferences
Trevi Therapeutics to Participate in Upcoming June Conferences PR Newswire
20.05.25 - PR Newswire
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough PR Newswire
08.05.25 - PR Newswire
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates PR Newswire

Newssuche

Videos

newspaper
07.04.26 +4,84%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »